MarginsXMarginsX
Home › Markets › Health Care › XFOR

X4 Pharmaceuticals Inc. (XFOR)

XFOR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.83
-9.29% on the day
Market cap
$289.0M
Micro cap
Revenue · 2025
$6.5M
+150.0% on 2024
Net income · 2025
-$79.2M
-1218.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1501697/000150169726000018/0001501697-26-000018-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerXFOR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2017
SEC CIK0001501697

Financials · 2025

LineValue
Revenue$6.5M
Net income-$79.2M
Operating income-$86.9M
Net margin-1218.4%
Operating margin-1336.7%
Revenue growth+150.0%
Cash$217.0M
Total assets$290.5M
P/E (computed)Net income was not positive
P/S (computed)44.5×

Warning signs

Cash runway
29.3 months
$185.8M cash at September 30, 2026
Share count, 1 year
+16.8%
2025-10-31 to 2026-11-02 · +1731.2% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$179K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Liquidity The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued."
10-Q 2026-11-04
Cash and burn$185.8M cash; operating cash flow -$19.0M a quarter.Report 2026-09-30
Shares outstanding102,113,554 (2026-11-02); 87,436,688 a year earlier; 167,291,209 three years earlier. 3y figure adjusted for splits (1-for-30 overall).Cover page 2026-11-02
Reverse splits, 3 years1; latest 1-for-30 on 2025-04-28Source 2025-04-28
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-05-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-26
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $250K, sold $429K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.8M-$20.2M-$20.2M$185.8M$75.0M$9.9M10-Q 2026-11-04
Q2 2026
2026-06-30
$2.4M-$16.2M-$20.8M$195.1M$75.0M$8.7M10-Q 2026-08-06
Q1 2026
2026-03-31
$2.5M-$20.2M-$19.6M$216.9M$75.0M$8.0M10-Q 2026-05-06
Q4 2025
2025-12-31
$2.2M-$23.9M-$15.5M$217.0M$75.0M$6.4M10-K 2026-03-17
Q3 2025
2025-09-30
$1.6M-$29.8M-$27.8M$69.6M$75.0M$5.7M10-Q 2026-11-04
Q2 2025
2025-06-30
$1.7M-$25.7M-$29.9M$39.2M$75.0M$4.7M10-Q 2026-08-06
Q1 2025
2025-03-31
$900K$282K-$12.4M$40.3M$75.0M$3.5M10-Q 2026-05-06
Q4 2024
2024-12-31
$1.5M-$39.8M-$33.0M$55.7M$75.0M$2.6M10-K 2026-03-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-1.9%
1 month+20.0%
3 months-27.3%
Year to date-22.0%
1 year-16.4%
From 52-week high-33.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
EDITEditas Medicine Inc.$1.87-13.82%$288.6M
SCTXScribe Therapeutics Inc.$15.37-6.05%$291.1M
EIKNEikon Therapeutics Inc.$5.38-9.95%$291.8M
AGENAgenus Inc.$6.29-6.54%$284.6M
AGMBAgomAb Therapeutics NV$5.97-6.13%$294.0M
TRXBTRex Bio Inc.$10.77-21.21%$295.6M
IPSCCentury Therapeutics Inc.$1.64-0.61%$297.8M
ALLOAllogene Therapeutics Inc.$0.8070-3.78%$279.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier